A Phase 1/2 interventional study of FT-2102 (olutasidenib) and Azacitidine in Acute Myeloid Leukemia, Acute Myelogenous Leukemia and Myelodysplastic Syndrome, sponsored by Forma Therapeutics, Inc.. Completed at 60 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.
Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 76th largest by enrollment of the 1,907 interventional ones that give a count, is one of 89 that started in 2016, is one of 306 in phase 1/2, and was the 1,255th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:
Uma Borate · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,078 · Phase 2 970 · Phase 3 139 · Phase 4 7
First in 1986; this study’s year is marked. 89 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 336 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 35 across the 1,907 interventional studies, 98 across the 126 observational. Of the 1,556 that completed or were terminated, 708 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
574 of 2,137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forma Therapeutics, Inc., one of the names counted as Novo Nordisk A/S. Under that name alone:
Forma Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Novo Nordisk A/S has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
170 of the studies in Leukemia, Myeloid, Acute with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
Add all 170 to your calendar (.ics) → With an account.
Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102 (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FT-2102 (olutasidenib)
Drug: FT-2102 (olutasidenib) · Drug: Azacitidine
Drug: FT-2102 (olutasidenib) · Drug: Cytarabine
Relapsed or Refractory (R/R) AML
Drug: FT-2102 (olutasidenib)
AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
Drug: FT-2102 (olutasidenib)
R/R AML/MDS, previously treated with FT-2102
Drug: FT-2102 (olutasidenib)
R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
Drug: FT-2102 (olutasidenib) · Drug: Azacitidine
R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
Drug: FT-2102 (olutasidenib) · Drug: Azacitidine
R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
Drug: FT-2102 (olutasidenib) · Drug: Azacitidine
Treatment naïve AML for whom standard treatments are contraindicated
Drug: FT-2102 (olutasidenib)
Treatment naïve AML who are candidates for azacitidine first line treatment
Drug: FT-2102 (olutasidenib) · Drug: Azacitidine
FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
azacitidine will be administered per site's standard of care
Also known as: Vidaza
low-dose cytarabine will be administered per site's standard of care
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE was defined as an adverse event (AE) that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported. Safety analysis set (SAS) included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).
Time frame: Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.
Time frame: Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria
Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\], Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts less than (\<) 5 percent (%) (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, absolute neutrophil count (ANC) greater than or equal to (\>=) 1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is defined as CR with unde-tectable IDH1m minimal residual disease (MRD) and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).
Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria
Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\]), Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts \<5 % (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, ANC \>=1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is de-fined as CR with undetectable IDH1m MRD and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).
Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria
Percentage of participants with complete remission (CR) is reported. CR is defined as bone marrow blast ≤ 5% myeloblasts with normal maturation of all cell lines, peripheral blood: Hgb ≥11 grams per deciliter (g/dL), platelets ≥ 100 × 10\^9/L, neutrophils ≥ 1.0 × 10\^9/L and blasts 0%.
Time frame: Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)
Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate
RFS is defined as the time between the date of first dose until relapse or death from any cause, whichever occurs first. RFS is calculated for all participants in Phase 2 Cohort 2. 4-Month RFS rate is defined as the percentage of participants in Phase 2 Cohort 2 who have not relapsed or died on or before their 4-month response evaluation.
Time frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 4 months)
Phase 1: Area Under the Curve (AUClast) for FT-2102
Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.
Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Phase 1: Maximum Plasma Concentration (Cmax) for FT-2102
Maximum plasma concentration (Cmax) for FT-2102 is presented.
Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Phase 1: Time to Maximum Plasma Concentration (Tmax) for FT-2102
Time to reach the maximum plasma concentration (Tmax) is presented.
Time frame: Phase 1: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Phase 1: Time to Response (TTR) for AML
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
Time frame: Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Phase 1: Duration of Overall Response for AML
Duration of response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.
Time frame: Phase 1: From date of the first response to the date of the relapse or death (up to 82 months)
Phase 1: Time to Response (TTR ) for MDS
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
Time frame: Phase 1: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Phase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML)
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
Time frame: Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML)
Duration of overall response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.
Time frame: Phase 2: From the date of the first response to the date of the relapse or death (up to 82 months)
Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS)
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
Time frame: Phase 2: Time from first dose of study drug until documentation of the first overall response (up to 82 months)
Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS)
Duration of overall response was calculated similarly to DCR but was assessed the time in months between documentation of the first response of PR or better until the date of relapse, death, whichever is earlier. The estimation of median duration of overall response was done by Kaplan-Meier method. The median duration of overall response is defined as the time at which 50% of the participants in a study have experienced the event of interest (relapse or death). Given the presence of only a single participant in the sample, there is an absence of variability in outcomes, and therefore, it was not possible to ascertain a time point at which half of the participants have experienced the event. Hence, median value could not be calculated.
Time frame: Phase 2: From the documentation of the first response of PR or better until the date of relapse, death, whichever is earlier (up to 82 months)
Phase 2, Cohort 2: Time to Relapse-Free Survival (RFS)
RFS was calculated for all participants in Phase 2 Cohort 2. RFS is defined as the time (in months) between the date of first dose until relapse or death from any cause, whichever occurs first. Relapse free survival time to event is reported for all participants in Cohort 2.
Time frame: Phase 2: From the date of first dose until relapse or death from any cause, whichever occurs first (up to 82 months)
Phase 2: Overall Survival (OS)
OS is defined as the time in months from the first dose of study drug until death from any cause. For the participants who are not known to have died by the end of study follow-up, OS will be censored on the date the participants was last known to be alive. OS is calculated using Kaplan-Meier method.
Time frame: Phase 2: From first dose of study drug until death from any cause (up to 82 months)
Phase 2: Event-free Survival (EFS)
EFS is defined as the time in months between first dose of study drug and disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy, whichever occurs first.
Time frame: Phase 2: From first dose of study drug to disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy (up to 82 months)
Phase 2: Transfusion Independence
Transfusion independence is defined as the number of participants who experience at least a 56-day period during any point on treatment without requiring a transfusion of RBC and/or platelet transfusion. Participants are classified as either "dependent" or "independent" at baseline based on their transfusion history. Those who received either platelets or pRBC or both within 8 weeks prior to the first dose of FT-2102 are considered "dependent". Number of participants with transfusion independent is reported here.
Time frame: Phase 2: From baseline (8 weeks prior to first dose) up to treatment period (up to 82 months)
Phase 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
A TEAE was defined as an AE that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A SAE is defined as any untoward medical occur-rence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported.
Time frame: Phase 2: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months)
Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
Time frame: Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Phase 2: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.
Time frame: Phase 2: From Baseline up to 28 days after last dose of study drug (up to 82 months)
Phase 2: Area Under the Curve (AUClast) for FT-2102
Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.
Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Phase 2: Maximum Plasma Concentration (Cmax) for FT-2102
Maximum Plasma Concentartion (Cmax) for FT-2102 is presented.
Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Phase 2: Time to Maximum Plasma Concentration (Tmax) for FT-2102
Time to reach the maximum plasma concentration (Tmax) for FT-2102 is presented.
Time frame: Phase 2: Cycle 1 Day 1 and Cycle 2 Day 1 (Cycle length= 28 days)
Total 336 participants enrolled in the study. In phase I, 78 participants were enrolled in single cohorts (FT-2102) and combination cohorts (FT-2102 with azacitidine/cytarabine) and in phase 2, 258 participants were enrolled in single cohorts (FT-2102) and combination cohorts (FT-2102 with azacitidine).
| Milestone | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 8 | 7 | 4 | 7 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 8 | 7 | 4 | 7 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 3 | 2 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Hsct transplant | 0 | 1 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 31 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 31 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Hsct transplant | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 153 | 18 | 5 | 20 | 21 | 20 | 10 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 153 | 18 | 5 | 20 | 21 | 20 | 10 | 11 |
| Withdrew: Protocol defined disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65 | 8 | 2 | 4 | 9 | 11 | 3 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 0 | 1 | 1 | 1 | 2 | 2 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 7 | 0 | 5 | 7 | 0 | 1 | 4 |
| Withdrew: Transplant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 2 | 0 | 6 | 1 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 0 | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 2 | 3 | 1 | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A TEAE was defined as an adverse event (AE) that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported. Safety analysis set (SAS) included all the participants who have received at least one dose of study drug (FT-2102, azacitidine, or cytarabine).
| Participants | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| TEAEs | 16 | 31 | 39 | 46 |
| SAEs | 10 | 23 | 30 | 36 |
Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
| Participants | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| Hematology: Hemoglobin; Increase(Grade <1) | 15 | 30 | 38 | 45 |
| Hematology: Hemoglobin; Increase (Grade 1) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 2) | 0 | 1 | 1 | 1 |
| Hematology: Hemoglobin; Increase (Grade 3) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Decrease (Grade <1) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Decrease (Grade 1) | 3 | 3 | 0 | 0 |
| Hematology: Hemoglobin; Decrease (Grade 2) | 1 | 7 | 9 | 10 |
| Hematology: Hemoglobin; Decrease (Grade 3) | 11 | 20 | 30 | 36 |
| Hematology: Hemoglobin; Decrease (Grade 4) | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Decrease(Grade 3 or 4) | 11 | 20 | 30 | 36 |
| Hematology: Platelets; Decrease (Grade <1) | 1 | 2 | 0 | 0 |
| Hematology: Platelets; Decrease (Grade 1) | 2 | 2 | 0 | 0 |
| Hematology: Platelets; Decrease (Grade 2) | 0 | 1 | 3 | 3 |
| Hematology: Platelets; Decrease (Grade 3) | 1 | 5 | 5 | 6 |
| Hematology: Platelets; Decrease (Grade 4) | 11 | 20 | 31 | 37 |
| Hematology: Platelets; Decrease (Grade 3 or 4) | 12 | 25 | 36 | 43 |
| Hematology: Leukocytes; Increase (Grade <1) | 14 | 28 | 36 | 43 |
| Hematology: Leukocytes; Increase (Grade 1) | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 3) | 1 | 2 | 3 | 3 |
| Hematology: Leukocytes; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 3 or 4) | 1 | 2 | 3 | 3 |
| Hematology: Leukocytes; Decrease (Grade <1) | 1 | 2 | 1 | 2 |
| Hematology: Leukocytes: Decrease (Grade 1) | 2 | 3 | 1 | 1 |
| Hematology: Leukocytes; Decrease (Grade 2) | 1 | 6 | 4 | 4 |
| Hematology: Leukocytes; Decrease (Grade 3) | 4 | 8 | 14 | 16 |
| Hematology: Leukocytes; Decrease (Grade 4) | 7 | 11 | 19 | 23 |
| Hematology: Leukocytes; Decrease (Grade 3 or 4) | 11 | 19 | 33 | 39 |
| Hematology: Neutrophils; Decrease (Grade <1) | 1 | 1 | 1 | 1 |
| Hematology: Neutrophils; Decrease (Grade 1) | 0 | 1 | 0 | 0 |
| Hematology: Neutrophils; Decrease (Grade 2) | 0 | 0 | 0 | 0 |
| Hematology: Neutrophils; Decrease (Grade 3) | 2 | 5 | 2 | 2 |
| Hematology: Neutrophils; Decrease (Grade 4) | 12 | 23 | 36 | 43 |
| Hematology: Neutrophils; Decrease (Grade 3 or 4) | 14 | 28 | 38 | 45 |
| Hematology: Lymphocytes; Increase (Grade <1) | 11 | 19 | 26 | 32 |
| Hematology: Lymphocytes; Increase (Grade 1) | 0 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Increase (Grade 2) | 3 | 10 | 11 | 12 |
| Hematology: Lymphocytes: Increase (Grade 3) | 0 | 0 | 1 | 1 |
| Hematology: Lymphocytes; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Increase (Grade 3 or 4) | 0 | 0 | 1 | 1 |
| Hematology: Lymphocytes; Decrease(Grade <1) | 1 | 3 | 2 | 2 |
| Hematology: Lymphocytes; Decrease(Grade 1) | 2 | 7 | 6 | 6 |
| Hematology: Lymphocytes; Decrease(Grade 2) | 5 | 6 | 10 | 14 |
| Hematology: Lymphocytes; Decrease(Grade 3) | 5 | 10 | 16 | 18 |
| Hematology: Lymphocytes; Decrease(Grade 4) | 1 | 3 | 4 | 5 |
| Hematology: Lymphocytes; Decrease(Grade 3 or 4) | 6 | 13 | 20 | 23 |
| Chemistry: Creatinine; Increase (Grade <1) | 0 | 3 | 2 | 3 |
| Chemistry: Creatinine; Increase (Grade 1) | 12 | 23 | 26 | 31 |
| Chemistry: Creatinine; Increase (Grade 2) | 3 | 4 | 10 | 11 |
| Chemistry: Creatinine; Increase (Grade 3) | 0 | 0 | 1 | 1 |
| Chemistry: Creatinine; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Creatinine; Increase (Grade 3 or 4) | 0 | 0 | 1 | 1 |
| Chemistry: Calcium; Increase (Grade <1) | 13 | 28 | 35 | 39 |
| Chemistry: Calcium; Increase (Grade 1) | 0 | 0 | 3 | 4 |
| Chemistry: Calcium; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade 3) | 1 | 1 | 0 | 1 |
| Chemistry: Calcium; Increase (Grade 4) | 1 | 1 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade 3 or 4) | 2 | 2 | 0 | 1 |
| Chemistry: Calcium; Decrease(Grade <1) | 6 | 12 | 13 | 16 |
| Chemistry: Calcium; Decrease(Grade 1) | 9 | 17 | 23 | 26 |
| Chemistry: Calcium; Decrease(Grade 2) | 0 | 1 | 1 | 1 |
| Chemistry: Calcium; Decrease(Grade 3) | 0 | 0 | 1 | 1 |
| Chemistry: Calcium; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Calcium; Decrease(Grade 3 or 4) | 0 | 0 | 1 | 1 |
| Chemistry: Magnesium; Increase(Grade <1) | 15 | 28 | 33 | 40 |
| Chemistry: Magnesium; Increase(Grade 1) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Increase(Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Increase(Grade 3) | 0 | 2 | 5 | 5 |
| Chemistry: Magnesium; Increase(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Increase(Grade 3 or 4) | 0 | 2 | 5 | 5 |
| Chemistry: Magnesium; Decrease(Grade <1) | 8 | 17 | 24 | 26 |
| Chemistry: Magnesium; Decrease(Grade 1) | 7 | 13 | 14 | 19 |
| Chemistry: Magnesium; Decrease(Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Decrease(Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Decrease(Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase(Grade <1) | 13 | 24 | 34 | 40 |
| Chemistry: Potassium; Increase(Grade 1) | 1 | 5 | 3 | 4 |
| Chemistry: Potassium; Increase(Grade 2) | 1 | 1 | 2 | 2 |
| Chemistry: Potassium; Increase(Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase(Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease(Grade <1) | 10 | 16 | 21 | 23 |
| Chemistry: Potassium; Decrease(Grade 1) | 3 | 10 | 14 | 19 |
| Chemistry: Potassium; Decrease(Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease(Grade 3) | 2 | 4 | 4 | 4 |
| Chemistry: Potassium; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease (Grade 3 or 4) | 2 | 4 | 4 | 4 |
| Chemistry: Sodium; Increase (Grade <1) | 13 | 27 | 34 | 41 |
| Chemistry: Sodium; Increase (Grade 1) | 2 | 3 | 5 | 5 |
| Chemistry: Sodium; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade <1) | 7 | 15 | 17 | 19 |
| Chemistry: Sodium; Decrease (Grade 1) | 7 | 11 | 19 | 24 |
| Chemistry: Sodium; Decrease (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade 3) | 1 | 4 | 3 | 3 |
| Chemistry: Sodium; Decrease (Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade 3 or 4) | 1 | 4 | 3 | 3 |
| Chemistry: Uric acid; Increase (Grade <1) | 10 | 21 | 25 | 31 |
| Chemistry: Uric acid; Increase (Grade 1) | 5 | 9 | 10 | 10 |
| Chemistry: Uric acid; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Uric acid; Increase (Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Uric acid; Increase (Grade 4) | 0 | 0 | 3 | 4 |
| Chemistry: Uric acid; Increase (Grade 3 or 4) | 0 | 0 | 3 | 4 |
| Chemistry: Albumin; Decrease(Grade <1) | 6 | 12 | 14 | 16 |
| Chemistry: Albumin; Decrease(Grade 1) | 5 | 10 | 12 | 12 |
| Chemistry: Albumin; Decrease(Grade 2) | 2 | 6 | 12 | 16 |
| Chemistry: Albumin; Decrease(Grade 3) | 2 | 2 | 0 | 1 |
| Chemistry: Albumin; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Albumin; Decrease(Grade 3 or 4) | 2 | 2 | 0 | 1 |
| Chemistry: Glucose; Increase (Grade <1) | 13 | 26 | 33 | 40 |
| Chemistry: Glucose; Increase (Grade 1) | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 3) | 1 | 2 | 5 | 5 |
| Chemistry: Glucose; Increase (Grade 4) | 1 | 2 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 3 or 4) | 2 | 4 | 5 | 5 |
| Chemistry: Glucose; Decrease(Grade <1) | 14 | 29 | 32 | 39 |
| Chemistry: Glucose; Decrease(Grade 1) | 1 | 1 | 5 | 5 |
| Chemistry: Glucose; Decrease(Grade 2) | 0 | 0 | 1 | 1 |
| Chemistry: Glucose; Decrease(Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Decrease(Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Chemistry: Lipase; Increase (Grade <1) | 2 | 2 | 18 | 18 |
| Chemistry: Lipase; Increase (Grade 1) | 1 | 1 | 0 | 0 |
| Chemistry: Lipase; Increase (Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Lipase; Increase (Grade 3) | 1 | 1 | 2 | 2 |
| Chemistry: Lipase; Increase (Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Lipase; Increase (Grade 3 or 4) | 1 | 1 | 2 | 2 |
| Chemistry: Amylase; Decrease(Grade <1) | 4 | 5 | 19 | 19 |
| Chemistry: Amylase; Decrease(Grade 1) | 0 | 0 | 0 | 0 |
| Chemistry: Amylase; Decrease(Grade 2) | 0 | 0 | 0 | 0 |
| Chemistry: Amylase; Decrease(Grade 3) | 0 | 0 | 0 | 0 |
| Chemistry: Amylase; Decrease(Grade 4) | 0 | 0 | 0 | 0 |
| Chemistry: Amylase; Decrease(Grade 3 or 4) | 0 | 0 | 0 | 0 |
| Coagulation: Activated partial Thromboplastin Time; Increase(Grade <1) | 6 | 7 | 20 | 21 |
| Coagulation: Activated partial Thromboplastin Time; Increase(Grade 1) | 1 | 1 | 2 | 2 |
| Coagulation: Activated partial Thromboplastin Time; Increase(Grade 2) | 0 | 0 | 1 | 1 |
| Coagulation: Activated partial Thromboplastin Time; Increase(Grade 3) | 0 | 0 | 1 | 1 |
| Coagulation: Activated partial Thromboplastin Time; Increase(Grade 4) | 0 | 0 | 0 | 0 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4) | 0 | 0 | 1 | 1 |
Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.
| Participants | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| <=450 msec | 10 | 16 | 23 | 26 |
| >450 to <=480 msec | 4 | 11 | 10 | 13 |
| >480 to <=500 msec | 0 | 2 | 1 | 2 |
| >500 msec | 1 | 1 | 4 | 4 |
| >30 to <=60 msec | 2 | 8 | 13 | 14 |
| >60 msec | 1 | 2 | 5 | 6 |
Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\], Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts less than (\<) 5 percent (%) (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, absolute neutrophil count (ANC) greater than or equal to (\>=) 1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is defined as CR with unde-tectable IDH1m minimal residual disease (MRD) and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).
| Percentage of participants | Phase 2: Cohort 1; FT-2102 (Single Agent) |
|---|---|
| Phase 2, Cohort 1: Percentage of Participants With Complete Remission (CR) Plus Complete Remission With Partial Hematological Recovery (CRh) for Acute Myeloid Leukemia Assessed by Investigator Based on International Working Group (IWG) Response Criteria | 35 (27.0 to 43.0) |
Percentage of participants with CR plus CRh (CR, Molecular CR \[CRm\]), Cytogenetic CR \[CRc\], CRh) is re-ported. CR is defined as bone marrow blasts \<5 % (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, ANC \>=1000/μL, platelet count \>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is de-fined as CR with undetectable IDH1m MRD and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \>50 × 10\^9/L and ANC \> 0.5 × 10\^9/L).
| Percentage of participants | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|
| Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria | 0 (0.0 to 52.2) | 47 (24.4 to 71.1) | 38 (13.9 to 68.4) | 30 (11.9 to 54.3) | 40 (12.2 to 73.8) | 45 (16.7 to 76.6) |
Percentage of participants with complete remission (CR) is reported. CR is defined as bone marrow blast ≤ 5% myeloblasts with normal maturation of all cell lines, peripheral blood: Hgb ≥11 grams per deciliter (g/dL), platelets ≥ 100 × 10\^9/L, neutrophils ≥ 1.0 × 10\^9/L and blasts 0%.
| Percentage of participants | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|
| Phase 2, Cohort 4 and 5: Percentage of Participants With CR for MDS Assessed by IWG Response Criteria | 0 (0.0 to 97.5) | 13 (0.3 to 52.7) |
RFS is defined as the time between the date of first dose until relapse or death from any cause, whichever occurs first. RFS is calculated for all participants in Phase 2 Cohort 2. 4-Month RFS rate is defined as the percentage of participants in Phase 2 Cohort 2 who have not relapsed or died on or before their 4-month response evaluation.
| Percentage of participants | Phase 2: Cohort 2; FT-2102 (Single Agent) |
|---|---|
| Phase 2, Cohort 2: Four-month Relapse Free Survival (RFS) Rate | 83 (58.6 to 96.4) |
Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.
| Hour*nanograms per millilitre (h*ng/mL) | Phase 1: FT-2102 100 mg QD (Single Agent) | Phase 1: FT-2102 150 mg QD (Single Agent) | Phase 1: FT-2102 300 mg QD (Single Agent) | Phase 1: FT-2102 150 mg BID (Single Agent) | Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy) | Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 5505 ± 146.9 | 8955 ± 63.7 | 12100 ± 75.4 | 2538 ± 34.2 | 8529 ± 51.1 | 2288 ± 71.7 |
| Cycle 2 Day 1 | 13080 ± 63.5 | 14130 ± 124.0 | 19140 ± 24.0 | 26360 ± 22.3 | 7468 ± 92.6 | 20640 ± 71.0 |
Maximum plasma concentration (Cmax) for FT-2102 is presented.
| Nanograms per millilitre (ng/mL) | Phase 1: FT-2102 100 mg QD (Single Agent) | Phase 1: FT-2102 150 mg QD (Single Agent) | Phase 1: FT-2102 300 mg QD (Single Agent) | Phase: FT-2102 150 mg BID (Single Agent) | Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy) | Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 571.5 ± 53.1 | 535.0 ± 58.7 | 708.0 ± 58.2 | 495.5 ± 37.4 | 543.3 ± 39.8 | 439.9 ± 56.2 |
| Cycle 2 Day 1 | 1913 ± 47.9 | 1998 ± 112.9 | 2907 ± 36.1 | 3703 ± 20.8 | 1101 ± 75.4 | 3183 ± 51.5 |
Time to reach the maximum plasma concentration (Tmax) is presented.
| hour | Phase 1: FT-2102 100 mg QD (Single Agent) | Phase 1: FT-2102 150 mg QD (Single Agent) | Phase 1: FT-2102 300 mg QD (Single Agent) | Phase 1: FT-2102 150 mg BID (Single Agent) | Phase 1: FT-2102 150 mg QD+Azacitidine (Combination Therapy) | Phase 1: FT-2102 150 mg BID+Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 4.05 (2.22 to 4.12) | 4.00 (2.02 to 24.00) | 23.83 (4.00 to 24.00) | 5.79 (1.00 to 7.83) | 4.02 (2.00 to 22.55) | 3.13 (2.03 to 4.12) |
| Cycle 2 Day 1 | 2.23 (2.13 to 4.00) | 2.00 (1.00 to 2.12) | 1.00 (0.00 to 1.08) | 3.00 (0.00 to 7.50) | 2.29 (2.00 to 4.00) | 1.18 (0.00 to 2.07) |
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
| Months | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| Phase 1: Time to Response (TTR) for AML | 1.90 (1.0 to 2.9) | 1.90 (1.0 to 4.7) | 1.90 (1.0 to 5.6) | 1.90 (1.0 to 5.6) |
Duration of response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.
| Months | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| Phase 1: Duration of Overall Response for AML | 3.60 (1.70 to NA) | 2.90 (0.90 to 6.40) | 22.00 (3.20 to NA) | 22.00 (3.20 to NA) |
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
| Months | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|
| Phase 1: Time to Response (TTR ) for MDS | 4.65 (1.0 to 8.3) | 4.65 (1.0 to 8.3) | 2.20 (1.0 to 8.5) | 2.20 (1.0 to 8.5) |
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
| Months | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|
| Phase 2: Time to Response (TTR) for Acute Myeloid Leukemia (AML) | 1.90 (0.9 to 10.2) | — | 1.80 (0.9 to 3.8) | 2.50 (1.0 to 4.2) | 2.50 (1.0 to 7.6) | 1.90 (1.8 to 3.9) | 2.80 (1.1 to 5.6) |
Duration of overall response is defined as the time from the date of the first response to the date of the relapse or death. The estimation of median duration of overall response was done by Kaplan-Meier method.
| Months | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|
| Phase 2: Duration of Overall Response for Acute Myeloid Leukemia (AML) | 14.80 (7.40 to 19.40) | 20.00 (1.90 to 28.80) | 7.25 (4.90 to NA) | 4.65 (2.80 to NA) | 10.60 (3.5 to 39.6) | 20.90 (5.60 to NA) |
TTR is the time in months between the first dose of study drug and documentation of the first overall response for participants who achieve a PR or better. This analysis was performed only on participants who have achieved PR or better as a best overall response.
| Months | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|
| Phase 2, Cohort 4 and Cohort 5: Time to Response (TTR) for Myelodysplastic Syndrome (MDS) | 3.30 (3.3 to 3.3) | 1.50 (1.0 to 13.0) |
Duration of overall response was calculated similarly to DCR but was assessed the time in months between documentation of the first response of PR or better until the date of relapse, death, whichever is earlier. The estimation of median duration of overall response was done by Kaplan-Meier method. The median duration of overall response is defined as the time at which 50% of the participants in a study have experienced the event of interest (relapse or death). Given the presence of only a single participant in the sample, there is an absence of variability in outcomes, and therefore, it was not possible to ascertain a time point at which half of the participants have experienced the event. Hence, median value could not be calculated.
| Months | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|
| Phase 2, Cohort 4 and Cohort 5: Duration of Overall Response for Myelodysplastic Syndrome (MDS) | NA (NA to NA) | 11.90 (2.80 to NA) |
RFS was calculated for all participants in Phase 2 Cohort 2. RFS is defined as the time (in months) between the date of first dose until relapse or death from any cause, whichever occurs first. Relapse free survival time to event is reported for all participants in Cohort 2.
| Months | Phase 2: Cohort 2; FT-2102 (Single Agent) |
|---|---|
| Phase 2, Cohort 2: Time to Relapse-Free Survival (RFS) | 18.40 (9.50 to NA) |
OS is defined as the time in months from the first dose of study drug until death from any cause. For the participants who are not known to have died by the end of study follow-up, OS will be censored on the date the participants was last known to be alive. OS is calculated using Kaplan-Meier method.
| Months | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Phase 2: Overall Survival (OS) | 11.60 (8.90 to 15.50) | NA (27.30 to NA) | 1.20 (1.10 to NA) | 25.20 (13.60 to NA) | 11.60 (5.00 to 27.50) | 10.20 (4.40 to 17.90) | 14.00 (1.00 to 19.10) | 18.70 (1.60 to NA) |
EFS is defined as the time in months between first dose of study drug and disease progression, relapse, death from any cause, treatment failure, or start of other (non-protocol study drug) new antileukemia therapy, whichever occurs first.
| Months | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Phase 2: Event-free Survival (EFS) | 5.50 (4.30 to 7.40) | 18.40 (9.50 to NA) | 1.05 (0.80 to NA) | 5.70 (1.90 to 16.40) | 7.80 (2.10 to 10.20) | 4.80 (2.50 to 9.70) | 5.50 (0.30 to NA) | 8.10 (1.60 to 33.00) |
Transfusion independence is defined as the number of participants who experience at least a 56-day period during any point on treatment without requiring a transfusion of RBC and/or platelet transfusion. Participants are classified as either "dependent" or "independent" at baseline based on their transfusion history. Those who received either platelets or pRBC or both within 8 weeks prior to the first dose of FT-2102 are considered "dependent". Number of participants with transfusion independent is reported here.
| Participants | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Phase 2: Transfusion Independence | 72 | 15 | 0 | 12 | 13 | 14 | 3 | 8 |
A TEAE was defined as an AE that emerges during treatment, having been absent pre-treatment, or worsens relative to the pre-treatment state. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. A SAE is defined as any untoward medical occur-rence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. Number of participants with TEAEs and SAEs is reported.
| Participants | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 153 | 18 | 5 | 19 | 21 | 19 | 10 | 11 |
| SAEs | 115 | 6 | 4 | 12 | 18 | 13 | 8 | 9 |
Number of participants with change from baseline in clinically significant abnormal laboratory values for hematology, chemistry and coagulation with Grade \<1 to 4 is reported. National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grade used to determine severity of AE. Grade 1: mild;asymptomatic/mild symptoms; Grade 2: moderate; minimal; Grade 3: severe/medically significant; Grade 4: life-threatening consequences, Grade 5: death.
| Participants | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Hematology: Hemoglobin; Increase (Grade <1) | 146 | 18 | 5 | 19 | 20 | 20 | 10 | 10 |
| Hematology: Hemoglobin; Increase (Grade 1) | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 3) | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hematology: Hemoglobin; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Increase (Grade 3 or 4) | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hematology: Hemoglobin; Decrease (Grade <1) | 3 | 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hematology: Hemoglobin; Decrease (Grade 1) | 17 | 8 | 0 | 1 | 0 | 2 | 1 | 0 |
| Hematology: Hemoglobin; Decrease (Grade 2) | 46 | 3 | 1 | 7 | 3 | 5 | 2 | 2 |
| Hematology: Hemoglobin; Decrease (Grade 3) | 86 | 4 | 4 | 11 | 18 | 12 | 7 | 9 |
| Hematology: Hemoglobin; Decrease (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Hemoglobin; Decrease (Grade 3 or 4) | 86 | 4 | 4 | 11 | 18 | 12 | 7 | 9 |
| Hematology: Platelets; Decrease (Grade <1) | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hematology: Platelets; Decrease (Grade 1) | 19 | 8 | 0 | 1 | 0 | 3 | 0 | 0 |
| Hematology: Platelets; Decrease (Grade 2) | 14 | 3 | 0 | 2 | 1 | 1 | 0 | 2 |
| Hematology: Platelets; Decrease (Grade 3) | 25 | 3 | 1 | 3 | 2 | 5 | 2 | 3 |
| Hematology: Platelets; Decrease (Grade 4) | 91 | 1 | 4 | 13 | 18 | 11 | 7 | 6 |
| Hematology: Platelets; Decrease (Grade 3 or 4) | 116 | 4 | 5 | 16 | 20 | 16 | 9 | 9 |
| Hematology: Leukocytes; Increase (Grade <1) | 150 | 18 | 5 | 18 | 20 | 19 | 10 | 11 |
| Hematology: Leukocytes; Increase (Grade 1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 3) | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Leukocytes; Increase (Grade 3 or 4) | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Hematology: Leukocytes; Decrease (Grade <1) | 17 | 1 | 2 | 0 | 2 | 2 | 3 | 0 |
| Hematology: Leukocytes; Decrease (Grade 1) | 8 | 2 | 0 | 0 | 1 | 3 | 0 | 0 |
| Hematology: Leukocytes; Decrease (Grade 2) | 20 | 7 | 0 | 3 | 0 | 0 | 2 | 0 |
| Hematology: Leukocytes; Decrease (Grade 3) | 50 | 6 | 1 | 4 | 6 | 5 | 3 | 4 |
| Hematology: Leukocytes; Decrease (Grade 4) | 57 | 2 | 2 | 12 | 12 | 10 | 2 | 7 |
| Hematology: Leukocytes; Decrease (Grade 3 or 4) | 107 | 8 | 3 | 16 | 18 | 15 | 5 | 11 |
| Hematology: Neutrophils; Decrease (Grade <1) | 1 | 2 | 0 | 1 | 0 | 3 | 1 | 0 |
| Hematology: Neutrophils; Decrease (Grade 1) | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hematology: Neutrophils; Decrease (Grade 2) | 6 | 5 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hematology: Neutrophils; Decrease (Grade 3) | 21 | 4 | 0 | 1 | 1 | 1 | 2 | 0 |
| Hematology: Neutrophils; Decrease (Grade 4) | 117 | 6 | 5 | 17 | 19 | 15 | 6 | 10 |
| Hematology: Neutrophils; Decrease (Grade 3 or 4) | 138 | 10 | 5 | 18 | 20 | 16 | 8 | 10 |
| Hematology: Lymphocytes; Increase (Grade <1) | 103 | 17 | 2 | 14 | 19 | 14 | 8 | 8 |
| Hematology: Lymphocytes; Increase (Grade 1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Increase (Grade 2) | 36 | 1 | 3 | 5 | 1 | 4 | 2 | 1 |
| Hematology: Lymphocytes; Increase (Grade 3) | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Increase (Grade 3 or 4) | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hematology: Lymphocytes; Decrease (Grade <1) | 18 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Hematology: Lymphocytes; Decrease (Grade 1) | 18 | 1 | 0 | 0 | 1 | 4 | 1 | 0 |
| Hematology: Lymphocytes; Decrease (Grade 2) | 36 | 7 | 0 | 7 | 4 | 4 | 3 | 3 |
| Hematology: Lymphocytes; Decrease (Grade 3) | 44 | 7 | 4 | 7 | 10 | 6 | 4 | 5 |
| Hematology: Lymphocytes; Decrease (Grade 4) | 27 | 1 | 0 | 4 | 5 | 3 | 1 | 0 |
| Hematology: Lymphocytes; Decrease (Grade 3 or 4) | 71 | 8 | 4 | 11 | 15 | 9 | 5 | 5 |
| Chemistry: Creatinine; Increase (Grade <1) | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Chemistry: Creatinine; Increase (Grade 1) | 92 | 13 | 3 | 13 | 10 | 14 | 3 | 8 |
| Chemistry: Creatinine; Increase (Grade 2) | 55 | 4 | 1 | 5 | 10 | 6 | 6 | 3 |
| Chemistry: Creatinine; Increase (Grade 3) | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Creatinine; Increase (Grade 4) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Creatinine; Increase (Grade 3 or 4) | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade <1) | 126 | 16 | 4 | 14 | 18 | 16 | 7 | 9 |
| Chemistry: Calcium; Increase (Grade 1) | 14 | 1 | 1 | 3 | 1 | 3 | 1 | 2 |
| Chemistry: Calcium; Increase (Grade 2) | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade 4) | 4 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Calcium; Increase (Grade 3 or 4) | 4 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Calcium; Decrease (Grade <1) | 83 | 13 | 4 | 14 | 13 | 16 | 4 | 6 |
| Chemistry: Calcium; Decrease (Grade 1) | 50 | 4 | 0 | 3 | 7 | 3 | 4 | 4 |
| Chemistry: Calcium; Decrease (Grade 2) | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Chemistry: Calcium; Decrease (Grade 3) | 2 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Chemistry: Calcium; Decrease (Grade 4) | 7 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Chemistry: Calcium; Decrease (Grade 3 or 4) | 9 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| Chemistry: Magnesium; Increase (Grade <1) | 129 | 18 | 3 | 15 | 18 | 19 | 9 | 10 |
| Chemistry: Magnesium; Increase (Grade 1) | 13 | 0 | 2 | 1 | 3 | 1 | 0 | 1 |
| Chemistry: Magnesium; Increase (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Increase (Grade 3) | 9 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Chemistry: Magnesium; Increase (Grade 4) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Increase (Grade 3 or 4) | 9 | 0 | 0 | 3 | 0 | 0 | 1 | 0 |
| Chemistry: Magnesium; Decrease (Grade <1) | 103 | 14 | 2 | 11 | 17 | 10 | 7 | 6 |
| Chemistry: Magnesium; Decrease (Grade 1) | 39 | 4 | 3 | 8 | 4 | 8 | 3 | 5 |
| Chemistry: Magnesium; Decrease (Grade 2) | 8 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Chemistry: Magnesium; Decrease (Grade 3) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Decrease (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Magnesium; Decrease (Grade 3 or 4) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase (Grade <1) | 120 | 12 | 5 | 17 | 16 | 16 | 7 | 9 |
| Chemistry: Potassium; Increase (Grade 1) | 28 | 4 | 0 | 2 | 4 | 2 | 3 | 2 |
| Chemistry: Potassium; Increase (Grade 2) | 4 | 2 | 0 | 0 | 1 | 2 | 0 | 0 |
| Chemistry: Potassium; Increase (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Increase (Grade 3 or 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease (Grade <1) | 73 | 14 | 1 | 7 | 16 | 12 | 6 | 5 |
| Chemistry: Potassium; Decrease (Grade 1) | 64 | 4 | 3 | 8 | 4 | 6 | 3 | 5 |
| Chemistry: Potassium; Decrease (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease (Grade 3) | 9 | 0 | 0 | 4 | 1 | 2 | 1 | 1 |
| Chemistry: Potassium; Decrease (Grade 4) | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Potassium; Decrease (Grade 3 or 4) | 15 | 0 | 1 | 4 | 1 | 2 | 1 | 1 |
| Chemistry: Sodium; Increase (Grade <1) | 139 | 17 | 4 | 18 | 19 | 20 | 9 | 8 |
| Chemistry: Sodium; Increase (Grade 1) | 13 | 0 | 0 | 1 | 2 | 0 | 1 | 3 |
| Chemistry: Sodium; Increase (Grade 2) | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Increase (Grade 3 or 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade <1) | 77 | 15 | 3 | 13 | 13 | 12 | 5 | 5 |
| Chemistry: Sodium; Decrease (Grade 1) | 62 | 2 | 2 | 5 | 8 | 7 | 4 | 6 |
| Chemistry: Sodium; Decrease (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade 3) | 12 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Chemistry: Sodium; Decrease (Grade 4) | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Chemistry: Sodium; Decrease (Grade 3 or 4) | 13 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Chemistry: Uric acid; Increase (Grade <1) | 96 | 10 | 5 | 11 | 14 | 3 | 5 | 11 |
| Chemistry: Uric acid; Increase (Grade 1) | 49 | 8 | 0 | 6 | 5 | 6 | 4 | 0 |
| Chemistry: Uric acid; Increase (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Uric acid; Increase (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Uric acid; Increase (Grade 4) | 6 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Chemistry: Uric acid; Increase (Grade 3 or 4) | 6 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Chemistry: Albumin; Decrease (Grade <1) | 57 | 16 | 0 | 7 | 8 | 9 | 3 | 5 |
| Chemistry: Albumin; Decrease (Grade 1) | 41 | 1 | 2 | 6 | 7 | 6 | 2 | 2 |
| Chemistry: Albumin; Decrease (Grade 2) | 45 | 1 | 2 | 6 | 4 | 4 | 2 | 4 |
| Chemistry: Albumin; Decrease (Grade 3) | 8 | 0 | 1 | 0 | 2 | 1 | 3 | 0 |
| Chemistry: Albumin; Decrease (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Albumin; Decrease (Grade 3 or 4) | 8 | 0 | 1 | 0 | 2 | 1 | 3 | 0 |
| Chemistry: Glucose; Increase (Grade <1) | 134 | 18 | 5 | 17 | 19 | 18 | 9 | 10 |
| Chemistry: Glucose; Increase (Grade 1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 3) | 16 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Chemistry: Glucose; Increase (Grade 4) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Increase (Grade 3 or 4) | 17 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Chemistry: Glucose; Decrease (Grade <1) | 136 | 15 | 5 | 17 | 18 | 19 | 10 | 10 |
| Chemistry: Glucose; Decrease (Grade 1) | 13 | 3 | 0 | 1 | 0 | 1 | 0 | 1 |
| Chemistry: Glucose; Decrease (Grade 2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Chemistry: Glucose; Decrease (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chemistry: Glucose; Decrease (Grade 4) | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Glucose; Decrease (Grade 3 or 4) | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Chemistry: Lipase; Increase (Grade <1) | 108 | 8 | 5 | 12 | 16 | 17 | 8 | 7 |
| Chemistry: Lipase; Increase (Grade 1) | 13 | 4 | 0 | 3 | 5 | 1 | 0 | 3 |
| Chemistry: Lipase; Increase (Grade 2) | 12 | 3 | 0 | 2 | 0 | 1 | 1 | 0 |
| Chemistry: Lipase; Increase (Grade 3) | 11 | 1 | 0 | 0 | 0 | 1 | 1 | 0 |
| Chemistry: Lipase; Increase (Grade 4) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Chemistry: Lipase; Increase (Grade 3 or 4) | 12 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Chemistry: Amylase; Decrease (Grade <1) | 116 | 13 | 5 | 13 | 18 | 18 | 9 | 9 |
| Chemistry: Amylase; Decrease (Grade 1) | 24 | 3 | 0 | 3 | 2 | 0 | 1 | 1 |
| Chemistry: Amylase; Decrease (Grade 2) | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Chemistry: Amylase; Decrease (Grade 3) | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Chemistry: Amylase; Decrease (Grade 4) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Chemistry: Amylase; Decrease (Grade 3 or 4) | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade <1) | 82 | 14 | 0 | 13 | 13 | 8 | 4 | 5 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 1) | 15 | 0 | 1 | 0 | 3 | 2 | 0 | 3 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 2) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coagulation: Activated partial Thromboplastin Time; Increase (Grade 3 or 4) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with change from baseline in clinically significant abnormal ECG parameter (QTcF) is reported. QT interval was the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTcF was the QT interval corrected for heart rate using Fridericia's formula: QTcF = QT divided by cube root of 60/heart rate.
| Participants | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| <=450 msec | 90 | 11 | 1 | 9 | 9 | 11 | 9 | 4 |
| >450 to <=480 msec | 44 | 3 | 3 | 6 | 7 | 5 | 0 | 4 |
| >480 to <=500 msec | 12 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| >500 msec | 5 | 2 | 0 | 2 | 3 | 3 | 0 | 2 |
| >30 to <=60 msec | 43 | 3 | 2 | 3 | 4 | 7 | 3 | 1 |
| >60 msec | 10 | 0 | 0 | 3 | 1 | 2 | 0 | 5 |
Area under the plasma concentration-time curve from zero time until the last measurable concentration is presented.
| h*ng/mL | Phase 2: Cohort 1; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2836 ± 59.5 | 2657 ± 36.8 | 1880 ± 77.4 | 3051 ± 109.7 | 2031 ± 69.4 | 1701 ± 39.4 | 4165 ± 116.5 | 3898 ± NA |
| Cycle 2 Day 1 | 20610 ± 69.7 | 27710 ± 14.9 | — | 19820 ± 77.6 | 19610 ± 62.1 | 21810 ± 45.6 | 25880 ± NA | 19940 ± NA |
Maximum Plasma Concentartion (Cmax) for FT-2102 is presented.
| ng/mL | Phase 2: Cohort 1; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 534.5 ± 57.5 | 492.4 ± 29.3 | 388.8 ± 49.1 | 623.2 ± 75.8 | 404.1 ± 58.5 | 411.2 ± 9.0 | 747.5 ± 107.6 | 671 ± NA |
| Cycle 2 Day 1 | 3136 ± 62.0 | 3800 ± 14.7 | — | 3239 ± 68.7 | 2934 ± 53.6 | 3043 ± 39.3 | 3500 ± NA | 3080 ± NA |
Time to reach the maximum plasma concentration (Tmax) for FT-2102 is presented.
| hour | Phase 2: Cohort 1; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 2; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 3; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 4; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 150 mg BID + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 150 mg BID (Single Agent) | Phase 2: Cohort 8; FT-2102 150 mg BID + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 4.00 (1.00 to 8.00) | 4.00 (2.00 to 8.00) | 5.00 (2.00 to 8.00) | 4.00 (2.00 to 8.00) | 4.00 (2.00 to 8.00) | 4.00 (2.00 to 8.00) | 3.00 (2.00 to 4.00) | 1.00 (1.00 to 1.00) |
| Cycle 2 Day 1 | 2.00 (0.00 to 8.00) | 1.00 (0.00 to 2.00) | — | 1.00 (0.00 to 8.00) | 1.00 (0.00 to 4.00) | 4.00 (0.00 to 8.00) | 0.00 (0 to 0) | 1.00 (1.00 to 1.00) |
Collected over From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: FT-2102 (Single Agent) | 4/16 (25%) | 10/16 (62.5%) | 15/16 (93.8%) |
| Phase 1: Total FT-2102 (Single Agent) | 11/31 (35.5%) | 23/31 (74.2%) | 29/31 (93.5%) |
| Phase 1: FT-2102 + Azacitidine (Combination Therapy) | 9/39 (23.1%) | 30/39 (76.9%) | 39/39 (100%) |
| Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | 10/46 (21.7%) | 36/46 (78.3%) | 46/46 (100%) |
| Phase 1: Overall | 21/78 (26.9%) | 60/78 (76.9%) | 76/78 (97.4%) |
| Phase 2: Cohort 1; FT-2102 (Single Agent) | 50/153 (32.7%) | 115/153 (75.2%) | 152/153 (99.3%) |
| Phase 2: Cohort 2; FT-2102 (Single Agent) | 0/18 (0%) | 6/18 (33.3%) | 18/18 (100%) |
| Phase 2: Cohort 3; FT-2102 (Single Agent) | 2/5 (40%) | 4/5 (80%) | 5/5 (100%) |
| Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | 3/20 (15%) | 12/20 (60%) | 18/20 (90%) |
| Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | 6/21 (28.6%) | 18/21 (85.7%) | 20/21 (95.2%) |
| Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | 7/20 (35%) | 13/20 (65%) | 19/20 (95%) |
| Phase 2: Cohort 7; FT-2102 (Single Agent) | 4/10 (40%) | 8/10 (80%) | 10/10 (100%) |
| Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) | 2/11 (18.2%) | 9/11 (81.8%) | 11/11 (100%) |
| Event | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Overall | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 3/16 | 6/31 | 8/39 | 10/46 | 16/78 | 23/153 | 1/18 | 2/5 | 2/20 | 4/21 | 2/20 | 2/10 | 2/11 |
| Disease progressionGeneral disorders | 0/16 | 3/31 | 4/39 | 5/46 | 8/78 | 25/153 | 0/18 | 1/5 | 3/20 | 4/21 | 3/20 | 1/10 | 3/11 |
| PneumoniaInfections and infestations | 2/16 | 7/31 | 5/39 | 7/46 | 14/78 | 14/153 | 0/18 | 1/5 | 1/20 | 4/21 | 2/20 | 1/10 | 0/11 |
| Acute promyelocytic leukaemia differentiation syndromeRespiratory, thoracic and mediastinal disorders | 1/16 | 2/31 | 2/39 | 4/46 | 6/78 | 14/153 | 0/18 | 0/5 | 1/20 | 2/21 | 0/20 | 2/10 | 0/11 |
| Cerebrovascular accidentNervous system disorders | 0/16 | 0/31 | 0/39 | 0/46 | 0/78 | 0/153 | 0/18 | 1/5 | 0/20 | 0/21 | 0/20 | 0/10 | 0/11 |
| Enterococcal bacteraemiaInfections and infestations | 0/16 | 0/31 | 0/39 | 0/46 | 0/78 | 0/153 | 0/18 | 1/5 | 1/20 | 0/21 | 0/20 | 0/10 | 0/11 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/16 | 0/31 | 0/39 | 0/46 | 0/78 | 2/153 | 0/18 | 1/5 | 0/20 | 0/21 | 0/20 | 0/10 | 0/11 |
| Respiratory alkalosisRespiratory, thoracic and mediastinal disorders | 0/16 | 0/31 | 0/39 | 0/46 | 0/78 | 0/153 | 0/18 | 1/5 | 0/20 | 0/21 | 0/20 | 0/10 | 0/11 |
| SyncopeNervous system disorders | 0/16 | 0/31 | 0/39 | 0/46 | 0/78 | 1/153 | 0/18 | 1/5 | 0/20 | 0/21 | 0/20 | 0/10 | 0/11 |
| Urinary tract infectionInfections and infestations | 0/16 | 1/31 | 1/39 | 1/46 | 2/78 | 1/153 | 0/18 | 1/5 | 1/20 | 0/21 | 0/20 | 1/10 | 0/11 |
| Event | Phase 1: FT-2102 (Single Agent) | Phase 1: Total FT-2102 (Single Agent) | Phase 1: FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | Phase 1: Overall | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/16 | 14/31 | 26/39 | 32/46 | 47/78 | 59/153 | 5/18 | 3/5 | 11/20 | 9/21 | 8/20 | 2/10 | 8/11 |
| ConstipationGastrointestinal disorders | 4/16 | 7/31 | 24/39 | 27/46 | 34/78 | 41/153 | 4/18 | 0/5 | 5/20 | 7/21 | 10/20 | 2/10 | 7/11 |
| HypokalaemiaMetabolism and nutrition disorders | 2/16 | 7/31 | 13/39 | 16/46 | 23/78 | 33/153 | 1/18 | 3/5 | 6/20 | 1/21 | 4/20 | 1/10 | 4/11 |
| Oedema peripheralGeneral disorders | 0/16 | 1/31 | 8/39 | 10/46 | 12/78 | 23/153 | 2/18 | 0/5 | 3/20 | 4/21 | 4/20 | 5/10 | 1/11 |
| VomitingGastrointestinal disorders | 3/16 | 8/31 | 14/39 | 17/46 | 25/78 | 27/153 | 2/18 | 0/5 | 10/20 | 6/21 | 6/20 | 2/10 | 4/11 |
| Platelet count decreasedInvestigations | 4/16 | 8/31 | 18/39 | 20/46 | 28/78 | 31/153 | 3/18 | 1/5 | 6/20 | 9/21 | 4/20 | 1/10 | 3/11 |
| DiarrhoeaGastrointestinal disorders | 5/16 | 7/31 | 16/39 | 21/46 | 29/78 | 31/153 | 1/18 | 1/5 | 5/20 | 7/21 | 5/20 | 2/10 | 4/11 |
| FatigueGeneral disorders | 6/16 | 13/31 | 16/39 | 19/46 | 32/78 | 35/153 | 6/18 | 2/5 | 6/20 | 6/21 | 7/20 | 2/10 | 0/11 |
| Abdominal painGastrointestinal disorders | 0/16 | 1/31 | 7/39 | 9/46 | 10/78 | 15/153 | 0/18 | 2/5 | 2/20 | 1/21 | 2/20 | 2/10 | 2/11 |
| Acute promyelocytic leukaemia differentiation syndromeRespiratory, thoracic and mediastinal disorders | 2/16 | 2/31 | 4/39 | 4/46 | 6/78 | 11/153 | 0/18 | 2/5 | 2/20 | 0/21 | 0/20 | 0/10 | 1/11 |
Full Analysis Set (FAS) included all the participants who were enrolled in the study and have received at least one dose of FT-2102.
| Age, Customized(Participants) | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 0 | 3 | 1 | 3 | 5 | 1 | 0 | 10 | 0 | 37 | 5 | 1 | 16 | 3 | 3 | 0 | 1 | 89 |
| 65 - <75 years | 0 | 3 | 4 | 0 | 1 | 5 | 6 | 14 | 0 | 68 | 11 | 3 | 2 | 9 | 9 | 3 | 6 | 144 |
| >=75 years | 3 | 2 | 2 | 1 | 1 | 2 | 3 | 7 | 1 | 48 | 2 | 1 | 2 | 9 | 8 | 7 | 4 | 103 |
| Sex: Female, Male(Participants) | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 5 | 2 | 2 | 5 | 5 | 5 | 14 | 0 | 74 | 6 | 2 | 11 | 7 | 10 | 6 | 2 | 158 |
| Male | 1 | 3 | 5 | 2 | 2 | 3 | 4 | 17 | 1 | 79 | 12 | 3 | 9 | 14 | 10 | 4 | 9 | 178 |
| Race (NIH/OMB)(Participants) | Phase 1: FT-2102 100mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Escalation) | Phase 1: FT-2102 300mg QD (Single Agent; Dose Escalation) | Phase 1: FT-2102 150mg QD+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Escalation) | Phase 1: FT-2102 150mg BID (Single Agent; Dose Expansion) | Phase 1: FT-2102 150mg BID+Azacitidine (Combination Therapy; Dose Expansion) | Phase 1: FT-2102 150mg BID+ Cytarabine (Combination Therapy; Dose Expansion) | Phase 2: Cohort 1; FT-2102 (Single Agent) | Phase 2: Cohort 2; FT-2102 (Single Agent) | Phase 2: Cohort 3; FT-2102 (Single Agent) | Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy) | Phase 2: Cohort 7; FT-2102 (Single Agent) | Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 5 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 5 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 15 |
| White | 3 | 5 | 7 | 2 | 6 | 6 | 8 | 19 | 1 | 71 | 10 | 4 | 11 | 14 | 13 | 5 | 6 | 191 |
| More than one race | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 7 | 0 | 56 | 7 | 0 | 8 | 4 | 7 | 5 | 3 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Dec 2023, 91 months.
Results were first posted in Jun 2025, 1 year 5 months after primary completion.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 91 months is above that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olutasidenib